China smartphone shipments slumped in June on inventory overhang: Jefferies
On Monday, Evercore ISI began coverage on ProQR Therapeutics N.V. (NASDAQ:PRQR), a biotechnology company with a market capitalization of $162 million, assigning an Outperform rating and establishing a price target of $5.00. The research firm’s analysis highlighted ProQR as a "true" biotech investment, emphasizing its early-stage position, emerging technology, and focus on diseases with serious unmet needs. According to InvestingPro data, the stock has shown strong momentum with an 8.3% gain over the past week.
The firm noted the high biology risk associated with ProQR’s work, alongside the nascent nature of the regulatory and commercial landscapes for its novel, first-in-class targets. Despite these challenges, Evercore ISI pointed to the company’s significant internal progress and external validation. InvestingPro analysis reveals that ProQR maintains a healthy balance sheet with more cash than debt and a strong current ratio of 3.95, though it’s worth noting the company is quickly burning through its cash reserves.
According to Evercore ISI, ProQR’s current stock price of $1.54, which trades at cash value, does not reflect the company’s true potential. The firm underlined that ProQR’s strategic options offer significantly underpriced optionality, which could lead to long-term value creation for investors. This potential for growth is a key reason behind the initiation of coverage with a $5 price target, while other analysts have set targets ranging from $4 to $15. InvestingPro subscribers can access 8 additional key insights about ProQR, including detailed financial health metrics and growth indicators.
ProQR Therapeutics specializes in developing treatments for rare genetic diseases, using its proprietary RNA therapy platform. The company’s pipeline includes therapies for conditions such as cystic fibrosis and Leber’s congenital amaurosis, a rare genetic eye disease. The company has demonstrated impressive revenue growth of 196% over the last twelve months, reflecting its development progress.
The Outperform rating suggests that Evercore ISI expects ProQR’s stock to perform better than the average return of the stocks the firm covers over the next 12 to 18 months. The $5 price target set by the firm represents their projection of the stock’s value per share over the same time horizon.
In other recent news, ProQR Therapeutics N.V. has been making significant strides with its RNA-editing platform, particularly with its lead candidate AX-0810. The company is set to file a Clinical Trial Application for AX-0810, targeting cholestatic diseases, with top-line data expected in the fourth quarter of 2025. Financially, ProQR reported collaboration revenue of €4.3 million and operating expenses of €14.5 million for the fourth quarter of 2024, with an EPS of €(0.09) and cash reserves of €149.4 million. Analysts have shown optimism, with H.C. Wainwright raising ProQR’s stock target to $12 while maintaining a Buy rating, and Raymond (NSE:RYMD) James reiterating a Strong Buy with a $14 target. Citi analysts also upgraded the stock to Buy, setting a $4 target, highlighting the potential market for AX-0810. Additionally, ProQR has strengthened its executive team by appointing Dennis Hom as Chief Financial Officer and Cristina Lopez Lopez as Chief Medical (TASE:BLWV) Officer. These appointments are aimed at advancing the company’s Axiomer RNA editing platform into clinical stages. The company plans to provide updates on various candidates, including AX-1412 for cardiovascular disease and AX-2402 for Rett Syndrome, with initial data anticipated in 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.